Impact Biomedical: Zoar files Form F-4 for merger; closing still subject to SEC, shareholder vote, listing

IMPACT BIOMEDICAL INC.

Zoar Limited filed Form F-4 with SEC on Sept 10, 2026 for proposed merger with Impact Biomedical (NYSE: IBO).
Combined company to focus on active pharmaceutical ingredients and intermediates for therapeutic areas.
Completion requires SEC effectiveness, Impact stockholder approval, and NYSE American listing of PubCo ordinary shares.
Preliminary proxy statement/prospectus included; definitive version to be mailed after effectiveness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.